The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia.

Bibliographic Details
Uniform Title:American psychiatric association practice guidelines (series)
Corporate Author: American Psychiatric Association (Author, Issuing body)
Language:English
Published: Arlington, VA : American Psychiatric Association, [2016]
Edition:First edition.
Series:American psychiatric association practice guidelines (series)
Subjects:
Dementia > Chemotherapy.
Antipsychotic drugs.
Dementia > drug therapy.
Dementia > complications.
Antipsychotic Agents > therapeutic use.
Psychomotor Agitation > drug therapy.
Psychotic Disorders > drug therapy.
Practice Guideline.
Genre:
Practice Guideline.
Physical Description:vii, 210 pages : illustrations ; 28 cm.
Variant Title:
Practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia
Format: Book

MARC

LEADER 00000cam a2200000 i 4500
001 in00005639223
003 OCoLC
005 20220616161142.0
008 160329s2016 vaua b 000 0 eng
010 |a  2016014829 
016 7 |a 101680037  |2 DNLM 
020 |a 9780890426777  |q (pbk. ;  |q alk. paper) 
020 |a 0890426775  |q (pbk. ;  |q alk. paper) 
035 |a (OCoLC)936533771 
040 |a DNLM/DLC  |b eng  |e rda  |c DLC  |d YDX  |d NLM  |d YDXCP  |d BTCTA  |d BDX  |d VET  |d U3G  |d OCLCQ  |d OCLCO  |d EEM  |d UtOrBLW 
042 |a pcc 
049 |a EEMR 
050 0 0 |a RC483  |b .A514 2016 
060 0 0 |a 2016 F-472 
060 1 0 |a WM 220 
060 4 |a WM 220  |b A512a 2016 
082 0 0 |a 616.89/18  |2 23 
110 2 |a American Psychiatric Association,  |e author,  |e issuing body.  |0 http://id.loc.gov/authorities/names/n79049301 
245 1 4 |a The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. 
246 3 |a Practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia 
250 |a First edition. 
264 1 |a Arlington, VA :  |b American Psychiatric Association,  |c [2016] 
300 |a vii, 210 pages :  |b illustrations ;  |c 28 cm. 
336 |a text  |b txt  |2 rdacontent 
337 |a unmediated  |b n  |2 rdamedia 
338 |a volume  |b nc  |2 rdacarrier 
490 1 |a American psychiatric association practice guidelines 
504 |a Includes bibliographical references. 
505 0 0 |g Machine generated contents note:  |t Overview of the Development Process --  |t Rating the Strength of Research Evidence and Recommendations --  |t Proper Use of Guidelines --  |t Guidelines and Implementation --  |t Guideline Statements --  |t Assessment of Behavioral/Psychological Symptoms of Dementia --  |t Development of a Comprehensive Treatment Plan --  |t Assessment of Benefits and Risks of Antipsychotic Treatment for the Patient --  |t Dosing, Duration, and Monitoring of Antipsychotic Treatment --  |t Use of Specific Antipsychotic Medications, Depending on Clinical Context --  |t Rationale --  |t Potential Benefits and Harms --  |t Benefits --  |t Harms --  |t Costs --  |t Balancing of Benefits and Harms in Rating the Strength of Recommendations --  |t Limitations of the Evidence in Assessing Benefits and Harms --  |t Implementation --  |t Assessment of Behavioral/Psychological Symptoms of Dementia --  |t Development of a Comprehensive Treatment Plan --  |t Assessment of Benefits and Risks of Antipsychotic Treatment for the Patient --  |t Dosing, Duration, and Monitoring of Antipsychotic Treatment --  |t Use of Specific Antipsychotic Medications, Depending on Clinical Context --  |t Quality Measurement Considerations --  |t Existing Measures of Relevance to Antipsychotic Use in Individuals With Dementia --  |t Variability in Practice That May Be Addressed by Quality Measures --  |t Potential Options for Measure Development --  |t Practical Barriers to Measure Development --  |t Additional Uses of Guideline Recommendations to Enhance Quality --  |t Guideline Development Process --  |t Management of Potential Conflicts of Interest --  |t Guideline Writing Group Composition --  |t Expert Opinion Data Collection --  |t Systematic Review Methodology --  |t Rating the Strength of Supporting Research Evidence --  |t Rating the Strength of Recommendations --  |t External Review --  |t Approval --  |t Glossary of Terms --  |t References --  |t Disclosures --  |t Individuals and Organizations That Submitted Comments --  |g Appendix  |t A Review of Available Evidence --  |t Clinical Questions --  |t Review of Supporting Research Evidence --  |g 1A.  |t Efficacy and Comparative Effectiveness of Second-Generation Antipsychotics for Overall BPSD --  |g 1B.  |t Efficacy and Comparative Effectiveness of Second-Generation Antipsychotics for Treatment of Agitation --  |g 1C.  |t Efficacy and Comparative Effectiveness of Second-Generation Antipsychotics for Treatment of Psychosis --  |g 2.  |t Appropriate Dosage and Duration of Antipsychotic Treatment in Individuals With Alzheimer's Disease and Other Dementia Syndromes --  |g 3.  |t Effects of Specific Patient Characteristics on Effectiveness and Harms of Antipsychotic Medications in Individuals With Dementia --  |g 4.  |t Potential Adverse Effects and/or Complications Involved With Prescribing Second-Generation Antipsychotics to Patients --  |g Appendix B  |t Expert Opinion Survey Data: Results --  |g Section I  |t Questions About Appropriate Use --  |g Section II  |t Duration of Treatment. 
650 0 |a Dementia  |x Chemotherapy.  |0 http://id.loc.gov/authorities/subjects/sh85036638 
650 0 |a Antipsychotic drugs.  |0 http://id.loc.gov/authorities/subjects/sh89002390 
650 1 2 |a Dementia  |x drug therapy.  |0 (DNLM)D003704Q000188 
650 1 2 |a Dementia  |x complications.  |0 (DNLM)D003704Q000150 
650 2 2 |a Antipsychotic Agents  |x therapeutic use.  |0 (DNLM)D014150Q000627 
650 2 2 |a Psychomotor Agitation  |x drug therapy.  |0 (DNLM)D011595Q000188 
650 2 2 |a Psychotic Disorders  |x drug therapy.  |0 (DNLM)D011618Q000188 
655 7 |a Practice Guideline.  |0 (DNLM)D017065  |2 lcgft 
776 0 8 |i Online version:  |a American Psychiatric Association, author, issuing body.  |t American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia.  |b First edition.  |d Arlington, VA : American Psychiatric Association, [2016]  |z 9780890426784  |w (DLC) 2016015843 
830 0 |a American psychiatric association practice guidelines (series) 
907 |y .b121838791  |b 170808  |c 170322 
998 |a mn  |b 170706  |c m  |d a   |e -  |f eng  |g vau  |h 4  |i 2 
994 |a C0  |b EEM 
999 f f |i 38b2ad83-4337-5dfd-876f-0731abb7d7ed  |s 3d5c01b0-da31-50fc-bf91-609cbce9ccd8  |t 0 
952 f f |p Can Circulate  |a Michigan State University-Library of Michigan  |b Michigan State University  |c MSU Main Library  |d MSU Main Library  |t 0  |e RC483 .A514 2016  |h Library of Congress classification  |i Printed Material  |m 31293035524978  |n 1